Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Radiology
Published in: European Radiology 5/2006

01-05-2006 | Experimental

Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis-avid contrast agent

Authors: Yicheng Ni, Feng Chen, Stefaan Mulier, Xihe Sun, Jie Yu, Willy Landuyt, Guy Marchal, Alfons Verbruggen

Published in: European Radiology | Issue 5/2006

Login to get access

Abstract

We exploited a necrosis-avid contrast agent ECIV-7 for magnetic resonance imaging (MRI) in rodent liver tumors after radiofrequency ablation (RFA). Rats bearing liver rhabdomyosarcoma (R1) were randomly allocated to three groups: group I, complete RFA, group II, incomplete RFA, and group III, sham ablation. Within 24 h after RFA, T1-weighted (T1-w) MRI was performed before and after injection of ECIV-7 at 0.05 mmol/kg and followed up from 6–24 h. Signal intensities (SIs) were measured with relative enhancement (RE) and contrast ratio (CR) calculated. The MRI findings were verified histomorphologically. On plain T1-w MRI the contrasts between normal liver, RFA lesion, residual and/or intact tumor were vague. Early after administration of ECIV-7, the liver SI was strongly enhanced (RE=40–50%), leaving the RFA lesion as a hypointense region in groups I and II. At delayed phase, two striking peri-ablational enhancement patterns appeared (RE=90% and CR=1.89%), i.e., “O” type of hyperintense rim in group I and “C” type of incomplete rim in group II. These MRI manifestations could be proven histologically. In this study, tissue components after RFA could be characterized with discernable contrasts by necrosis-avid contrast agent (NACA)-enhanced MRI, especially at delayed phase. This approach may prove useful for defining the ablated area and identifying residual tumor after RFA.
Literature
1.
Ni Y, Mulier S, Miao Y, Michel L, Marchal G (2005) A review of the general aspects of radiofrequency ablation. Abdom Imaging 30:381–400CrossRefPubMed
2.
Hynynen K, McDannold N (2004) MRI guided and monitored focused ultrasound thermal ablation methods: a review of progress. Int J Hyperthermia. 20:725–737CrossRefPubMed
3.
Antoch G, Vogt FM, 4 P, Freudenberg LS, Blechschmid N, Dirsch O, Bockisch A, Forsting M, Debatin JF, Kuehl H (2005) Assessment of liver tissue after radiofrequency ablation: findings with different imaging procedures. J Nucl Med 46:520–525PubMed
4.
Dromain C, de Baere T, Elias D, Kuoch V, Ducreux M, Boige V, Petrow P, Roche A, Sigal R (2002) Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology 223:255–262PubMedCrossRef
5.
Tsuda M, Majima K, Yamada T, Saitou H, Ishibashi T, Takahashi S (2001) Hepatocellular carcinoma after radiofrequency ablation therapy: dynamic CT evaluation of treatment. Clin Imaging. 25:409–415CrossRefPubMed
6.
Bartolozzi C, Crocetti L, Cioni D, Donati FM, Lencioni R (2001) Assessment of therapeutic effect of liver tumor ablation procedures. Hepatogastroenterology. 48:352–358PubMed
7.
Kim TJ, Moon WK, Cha JH, et al (2005) VX2 carcinoma in rabbits after radiofrequency ablation: Comparison of MR contrast agents for help in differentiating benign periablational enhancement from residual tumor. Radiology 234:423–430PubMedCrossRef
8.
Goldberg SN (2005) Can we differentiate residual untreated tumor from tissue responses to heat following thermal tumor ablation? Radiology 234:317–318PubMedCrossRef
9.
Ni Y, Chen F, Marchal G (2005) Differentiation of residual tumor from benign periablational tissues after radiofrequency ablation: the role of MRI contrast agents (letter). Radiology 237:745–749PubMedCrossRef
10.
Ni Y, Bormans G, Chen F, Verbruggen A, Marchal G (2005) Necrosis avid contrast agents: functional similarity versus structural diversity (review). Invest Radiol 40:526–535CrossRefPubMed
11.
Marchal G, Ni Y, Herijgers P, Flameng W, Petré C, Bosmans H, Yu J, Ebert W, Hilger CS, Pfefferer D, Semmler W, Baert AL (1996) Paramagnetic metalloporphyrins: infarct avid contrast agents for diagnosis of acute myocardial infarction by magnetic resonance imaging. Eur Radiol 6:1–8CrossRefPubMed
12.
Ni Y, Marchal G, Herijgers P, et al (1996) Paramagnetic metalloporphyrins: from enhancers for malignant tumors to markers of myocardial infarcts. Acad Radiol 3:S395–S397CrossRefPubMed
13.
Ni Y (1998) Myocardial viability. In: Bogaert J, Duerinckx AL, Rademakers FE (eds) Magnetic resonance of the heart and great vessels: clinical applications, 1st edn, Springer, Berlin Heidelberg New York, pp 113–132
14.
Pislaru S, Ni Y, Pislaru C, Bosmans H, Miao Y, Bogaert J, Semmler W, Marchal G, Van de Werf F (1999) Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent. Circulation 99:690–696PubMed
15.
Choi SI, Choi SH, Kim ST, Lim KH, Lim CH, Gong GY, Kim HY, Weinmann HJ, Lim TH (2000) Irreversibly damaged myocardium at MR imaging with a necrotic tissue-specific contrast agent in a cat model. Radiology 215:863–868PubMed
16.
Ni Y, Pislaru C, Bosmans H, Pislaru S, Miao Y, Bogaert J, Dymarkowski S, Yu J, Semmler W, Van de Werf F, Baert AL, Marchal G (2001) Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging. Eur Radiol 11:876–883CrossRefPubMed
17.
Saeed M, Lund G, Wendland MF, et al (2001) Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction with necrosis-specific and extracellular nonspecific contrast media. Circulation 103:871–876PubMed
18.
Ni Y, Dymarkowski S, Chen F, Bogaert J, and Marchal G (2002) Occlusive myocardial infarction: enhanced or not enhanced with necrosis avid contrast agents at magnetic resonance imaging. Radiology 225:603–605PubMedCrossRef
19.
Ni Y, Cresens E, Adriaens P, Dymarkowski S, Bogaert J, Zhang H, Bosmans H, Verbruggen A, Marchal G (2002) Exploring multifunctional features of necrosis avid contrast agents. Acad Radiol 9 [Suppl 2]:S488–S490CrossRefPubMed
20.
Hermens AF, Barendsen GW (1967) Cellular proliferation patterns in an experimental rhabdomyosarcoma in the rat. Eur J Cancer 3:361–369PubMed
21.
Chen F, Sun X, De Keyzer F, Yu J, Peeters R, Coudyzer W, Vandecaveye V, Bosmans H, Van Hecke P, Landuyt W, Hermans R, Marchal G, Ni Y (2005) A rodent liver tumor model with implanted rhabdomyosarcoma: characterization using magnetic resonance, microangiography and histopathology. Radiology (in press)
22.
Cresens E, Ni Y, Adriaens P, Verbruggen A, Marchal G (2001) Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them. International Patent Application PCT/BE01/00192 (7 November 2001)
23.
Marchal G, Verbruggen A, Ni Y, Adriaens P, Cresens E (1999) Non-porphyrin compounds for use as a diagnosticum and/or pharmaceutical. International Patent Application PTC /BE99/00104 (5 August 1999)
24.
Ni Y, Petré C, Miao Y, et al (1997) Magnetic resonance imaging—histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis. Invest Radiol 32:770–779CrossRefPubMed
25.
Ni Y, Adzamli K, Miao Y, et al (2001) MRI contrast enhancement of necrosis by MP-2269 and Gadophrin-2 in a rat model of liver infarction. Invest Radiol 36:97–103CrossRefPubMed
26.
Coad JE, Kosari K, Humar A, Sielaff TD (2003) Radiofrequency ablation causes thermal fixation of hepatocellular carcinoma: a post-liver transplant histopathologic study. Clin Transpl 17:377–384CrossRef
27.
Miao Y, Ni Y, Mulier S, et al (2000) Treatment of VX2 liver tumor in rabbits with “wet” electrode mediated radio-frequency ablation. Eur Radiol 10:188–194CrossRefPubMed
28.
Solbiati L, Livraghi T, Goldberg SN, et al (2001) Percutaneous radio-frequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology. 221:159–166PubMedCrossRef
29.
Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H (2005) Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol (in press), 2005 May 3 [Epub ahead of print]
30.
Langenhoff BS, Oyen WJ, Jager GJ, et al (2002) Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol. 20:4453–4458CrossRefPubMed
31.
Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H (2003) FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 28:192–197CrossRefPubMed
32.
Shreve PD, Anzai Y, Wahl RL (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19:61–77PubMed
33.
Cook GJ, Maisey MN, Fogelman I (1999) Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med. 26:1363–1378CrossRefPubMed
34.
Ni Y, Marchal G (1998) Enhanced magnetic resonance imaging for tissue characterization of liver abnormalities with hepatobiliary contrast agents: an overview of preclinical animal experiments (review). Top Magn Reson Imaging 9:183–195PubMedCrossRef
35.
Peng Q, Nesland JM (2004) Effects of photodynamic therapy on tumor stroma. Ultrastruct Pathol 28:333–340CrossRefPubMed
36.
Van de Putte M, Roskams T, Vandenheede JR, Agostinis P, de Witte PA (2005) Elucidation of the tumoritropic principle of hypericin. Br J Cancer 92:1406–1413CrossRefPubMed
37.
Ni Y, Chen F, Bormans G, Verbruggen A, Marchal G (2005) Targeting stroma: natural mechanisms derived from photodynamic therapy (PDT) and necrosis avid contrast agents (NACAs)? Mol Imaging 4:382 (abstract ID 556)
38.
Kim TK, Choi BI, Park SW, Lee W, Han JK, Han MC, Weinmann HJ (2000) Gadolinium mesoporphyrin as an MR imaging contrast agent in the evaluation of tumors: an experimental model of VX2 carcinoma in rabbits. AJR Am J Roentgenol 175: 227–234PubMed
39.
Ju Lee H, Kim IO, Kim TK, Hyung Kim S, Choi JI, Woo Lee J, Kyung Moon W, Choi BI, Chung Han M, Weinmann HJ, Hyun Chang K (2002) Dynamic enhancement features of gadophrin-2 on magnetic resonance imaging: an experimental model of VX2 carcinoma and bacterial abscess in rabbit thigh. Invest Radiol 37:663–671CrossRefPubMed
Metadata
Title
Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis-avid contrast agent
Authors
Yicheng Ni
Feng Chen
Stefaan Mulier
Xihe Sun
Jie Yu
Willy Landuyt
Guy Marchal
Alfons Verbruggen
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
European Radiology / Issue 5/2006
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-005-0094-0

Other articles of this Issue 5/2006

European Radiology 5/2006 Go to the issue

Neuro

Detection of lesions in multiple sclerosis by 2D FLAIR and single-slab 3D FLAIR sequences at 3.0 T: initial results

Interpretation Corner

An incidental finding in a young woman (2006: 2b)

Letter to the Editor

VQ scintigram in the CT pulmonary angiogram era

Gastrointestinal

Preoperative staging of rectal cancer: accuracy of 3-Tesla magnetic resonance imaging

Contrast Media

Development of water-soluble metallofullerenes as X-ray contrast media

Vascular interventional

Analysis of haemodynamic disturbance in the atherosclerotic carotid artery using computational fluid dynamics